1
|
Inhibition of PDE10A-Rescued TBI-Induced Neuroinflammation and Apoptosis through the cAMP/PKA/NLRP3 Pathway. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2022; 2022:3311250. [PMID: 35463083 PMCID: PMC9019408 DOI: 10.1155/2022/3311250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 01/22/2022] [Accepted: 03/22/2022] [Indexed: 11/18/2022]
Abstract
Phosphodiesterase 10A (PDE10A) is a dual-substrate phosphodiesterase that is highly expressed in the striatal complex. PDE10A is an important target for the treatment of ganglion dysfunction and neuroinflammation-related diseases, but its possible impact on traumatic brain injury (TBI) is still unclear. This study aims to investigate the protective effects of inhibiting PDE10A on neuroinflammation post-TBI injury and its possible molecular mechanism. The expression of PDE10A in rats and HT22 cells was determined by Western blotting. The neurological dysfunction of these rats was detected by Nissl staining, hematoxylin-eosin (HE) staining, and Morris water maze test. The activity of HT22 cells was measured by MTT. The findings of this study suggest that PDE10A is highly expressed in the brain tissue of TBI rats and HT22 cells induced by mechanical injury. Inhibition of PDE10A reduces the expression of interleukin-1β (IL-1β) and interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in HT22 cells induced by mechanical injury to inhibit cell apoptosis. Simultaneously, inhibition of PDE10A in TBI rats reduces the time to find a visible platform in the same pool, while cAMP/PKA activator treatment alleviates all of the abovementioned phenomena. Additionally, it is further confirmed that inhibition of PDE10A activates the cAMP/PKA pathway and downregulates the expression of NRLP3. These findings demonstrate that inhibition of PDE10A exerts neuroprotection by inhibiting apoptosis and inflammation following TBI, at least partially by the cAMP/PKA/NLRP3 pathway.
Collapse
|
2
|
Luo L, Cai Y, Zhang Y, Hsu CG, Korshunov VA, Long X, Knight PA, Berk BC, Yan C. Role of PDE10A in vascular smooth muscle cell hyperplasia and pathological vascular remodelling. Cardiovasc Res 2021; 118:2703-2717. [PMID: 34550322 PMCID: PMC9890476 DOI: 10.1093/cvr/cvab304] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 09/17/2021] [Indexed: 02/05/2023] Open
Abstract
AIMS Intimal hyperplasia is a common feature of vascular remodelling disorders. Accumulation of synthetic smooth muscle cell (SMC)-like cells is the main underlying cause. Current therapeutic approaches including drug-eluting stents are not perfect due to the toxicity on endothelial cells and novel therapeutic strategies are needed. Our preliminary screening for dysregulated cyclic nucleotide phosphodiesterases (PDEs) in growing SMCs revealed the alteration of PDE10A expression. Herein, we investigated the function of PDE10A in SMC proliferation and intimal hyperplasia both in vitro and in vivo. METHODS AND RESULTS RT-qPCR, immunoblot, and in situ proximity ligation assay were performed to determine PDE10A expression in synthetic SMCs and injured vessels. We found that PDE10A mRNA and/or protein levels are up-regulated in cultured SMCs upon growth stimulation, as well as in intimal cells in injured mouse femoral arteries. To determine the cellular functions of PDE10A, we focused on its role in SMC proliferation. The anti-mitogenic effects of PDE10A on SMCs were evaluated via cell counting, BrdU incorporation, and flow cytometry. We found that PDE10A deficiency or inhibition arrested the SMC cell cycle at G1-phase with a reduction of cyclin D1. The anti-mitotic effect of PDE10A inhibition was dependent on cGMP-dependent protein kinase Iα (PKGIα), involving C-natriuretic peptide (CNP) and particulate guanylate cyclase natriuretic peptide receptor 2 (NPR2). In addition, the effects of genetic depletion and pharmacological inhibition of PDE10A on neointimal formation were examined in a mouse model of femoral artery wire injury. Both PDE10A knockout and inhibition decreased injury-induced intimal thickening in femoral arteries by at least 50%. Moreover, PDE10A inhibition decreased ex vivo remodelling of cultured human saphenous vein segments. CONCLUSIONS Our findings indicate that PDE10A contributes to SMC proliferation and intimal hyperplasia at least partially via antagonizing CNP/NPR2/cGMP/PKG1α signalling and suggest that PDE10A may be a novel drug target for treating vascular occlusive disease.
Collapse
Affiliation(s)
- Lingfeng Luo
- Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA,Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Yujun Cai
- Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Yishuai Zhang
- Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Chia G Hsu
- Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Vyacheslav A Korshunov
- Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Xiaochun Long
- Department of Vascular Biology Center and Medicine, Medical College of Georgia, Augusta, GA, USA
| | - Peter A Knight
- Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Bradford C Berk
- Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Chen Yan
- Corresponding author. Tel: 585-276-7704, E-mail:
| |
Collapse
|
3
|
Wang Y, Gao H, Jiang S, Luo Q, Han X, Xiong Y, Xu Z, Qiao R, Yang X. Principal component analysis of routine blood test results with Parkinson's disease: A case-control study. Exp Gerontol 2020; 144:111188. [PMID: 33279667 DOI: 10.1016/j.exger.2020.111188] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 08/27/2020] [Accepted: 11/24/2020] [Indexed: 11/26/2022]
Abstract
This study aimed to explore the association of routine blood test values and blood cell ratios with the risk or severity of Parkinson's disease (PD). The medical records of 453 PD patients and 436 controls were retrospectively reviewed. The severity of PD was quantified by the modified Hoehn-Yahr (HY) scale. We performed principal component analysis (PCA) of significant values/ratios and used logistic regression analysis to explore the relationship between principal components (PCs) and the risk of PD. Spearman correlation and ordinal logistic regression analyses were performed to explore the relationship between indicators and the severity of PD. The PCA generated 9 PCs, which contributed to 90.86% of the total variance. Logistic regression analysis revealed positive associations of PC2 (a measure monocyte ratios) and PC6 (a measure of platelet ratios and volume) and negative associations of PC1 (a comprehensive measure of lymphocyte, eosinophil, neutrophil, and red blood cell values), PC4 (a measure of red blood cell values), and PC7 (a measure of red blood cell values and platelet volume) with the risk of PD. However, we observed no associations of variables with the severity of PD. In conclusion, PCA reduced the dimensionality of the data. Peripheral blood disorders may be associated with PD.
Collapse
Affiliation(s)
- Yuling Wang
- Medicine VIP, First Affiliated Hospital of Xinjiang Medical University, No. 137, Liyushanlu Road, Urumqi 830011, China; Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, No. 38, Nanhudonglu Road, Urumqi 830054, China
| | - Hua Gao
- Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, No. 38, Nanhudonglu Road, Urumqi 830054, China; Department of Neurology, Fifth Affiliated Hospital of Xinjiang Medical University, No. 118, Henanxilu Road, Urumqi 830000, China
| | - Sen Jiang
- Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, No. 38, Nanhudonglu Road, Urumqi 830054, China
| | - Qin Luo
- Department of Medicine, Tumor Hospital Affiliated of Xinjiang Medical University, No. 789, Suzhoudongjie Road, Urumqi 830000, China
| | - Xuejie Han
- Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, No. 38, Nanhudonglu Road, Urumqi 830054, China
| | - Yi Xiong
- Department of Neurology, First Affiliated Hospital of Xinjiang Medical University, No. 137, Liyushanlu Road, Urumqi 830011, China
| | - Zeheng Xu
- Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, No. 38, Nanhudonglu Road, Urumqi 830054, China
| | - Rui Qiao
- Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, No. 38, Nanhudonglu Road, Urumqi 830054, China
| | - Xinling Yang
- Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, No. 38, Nanhudonglu Road, Urumqi 830054, China.
| |
Collapse
|
4
|
Malig TC, Tan Y, Wisniewski SR, Higman CS, Carrasquillo-Flores R, Ortiz A, Purdum GE, Kolotuchin S, Hein JE. Development of a telescoped synthesis of 4-(1 H)-cyanoimidazole core accelerated by orthogonal reaction monitoring. REACT CHEM ENG 2020. [DOI: 10.1039/d0re00234h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Telescoped synthesis enabled by reaction monitoring.
Collapse
Affiliation(s)
- Thomas C. Malig
- Department of Chemistry
- University of British Columbia
- Vancouver
- Canada
| | - Yichen Tan
- Chemical Process Development
- Bristol Myers Squibb Company
- New Brunswick
- USA
| | | | - Carolyn S. Higman
- Chemical Process Development
- Bristol Myers Squibb Company
- New Brunswick
- USA
| | | | - Adrian Ortiz
- Chemical Process Development
- Bristol Myers Squibb Company
- New Brunswick
- USA
| | - Geoffrey E. Purdum
- Chemical Process Development
- Bristol Myers Squibb Company
- New Brunswick
- USA
| | - Sergei Kolotuchin
- Chemical Process Development
- Bristol Myers Squibb Company
- New Brunswick
- USA
| | - Jason E. Hein
- Department of Chemistry
- University of British Columbia
- Vancouver
- Canada
| |
Collapse
|
5
|
Imidazole Derivatives as Promising Agents for the Treatment of Chagas Disease. Antimicrob Agents Chemother 2019; 63:AAC.02156-18. [PMID: 30670432 DOI: 10.1128/aac.02156-18] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2018] [Accepted: 01/13/2019] [Indexed: 12/17/2022] Open
Abstract
More than 100 years after being first described, Chagas disease remains endemic in 21 Latin American countries and has spread to other continents. Indeed, this disease, which is caused by the protozoan parasite Trypanosoma cruzi, is no longer just a problem for the American continents but has become a global health threat. Current therapies, i.e., nifurtimox and benznidazole (Bz), are far from being adequate, due to their undesirable effects and their lack of efficacy in the chronic phases of the disease. In this work, we present an in-depth phenotypic evaluation in T. cruzi of a new class of imidazole compounds, which were discovered in a previous phenotypic screen against different trypanosomatids and were designed as potential inhibitors of cAMP phosphodiesterases (PDEs). The confirmation of several activities similar or superior to that of Bz prompted a synthesis program of hit optimization and extended structure-activity relationship aimed at improving drug-like properties such as aqueous solubility, which resulted in additional hits with 50% inhibitory concentration (IC50) values similar to that of Bz. The cellular effects of one representative hit, compound 9, on bloodstream trypomastigotes were further investigated. Transmission electron microscopy revealed cellular changes, after just 2 h of incubation with the IC50 concentration, that were consistent with induced autophagy and osmotic stress, mechanisms previously linked to cAMP signaling. Compound 9 induced highly significant increases in both cellular and medium cAMP levels, confirming that inhibition of T. cruzi PDE(s) is part of its mechanism of action. The potent and selective activity of this imidazole-based PDE inhibitor class against T. cruzi constitutes a successful repurposing of research into inhibitors of mammalian PDEs.
Collapse
|
6
|
Botros SS, William S, Sabra ANA, El-Lakkany NM, Seif El-Din SH, García-Rubia A, Sebastián-Pérez V, Blaazer AR, de Heuvel E, Sijm M, Zheng Y, Salado IG, Munday JC, Maes L, de Esch IJP, Sterk GJ, Augustyns K, Leurs R, Gil C, De Koning HP. Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity. INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE 2019; 9:35-43. [PMID: 30669086 PMCID: PMC6350229 DOI: 10.1016/j.ijpddr.2019.01.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Revised: 01/10/2019] [Accepted: 01/13/2019] [Indexed: 01/10/2023]
Abstract
We report the evaluation of 265 compounds from a PDE-focused library for their antischistosomal activity, assessed in vitro using Schistosoma mansoni. Of the tested compounds, 171 (64%) displayed selective in vitro activity, with 16 causing worm hypermotility/spastic contractions and 41 inducing various degrees of worm killing at 100 μM, with the surviving worms displaying sluggish movement, worm unpairing and complete absence of eggs. The compounds that did not affect worm viability (n = 72) induced a complete cessation of ovipositing. 82% of the compounds had an impact on male worms whereas female worms were barely affected. In vivo evaluation in S. mansoni-infected mice with the in vitro 'hit' NPD-0274 at 20 mg/kg/day orally for 5 days resulted in worm burden reductions of 29% and intestinal tissue egg load reduction of 35% at 10 days post-treatment. Combination of praziquantel (PZQ) at 10 mg/kg/day for 5 days with NPD-0274 or NPD-0298 resulted in significantly higher worm killing than PZQ alone, as well as a reduction in intestinal tissue egg load, disappearance of immature eggs and an increase in the number of dead eggs.
Collapse
Affiliation(s)
- Sanaa S Botros
- Pharmacology Department, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, P.O. Box 30, Giza, 12411, Egypt
| | - Samia William
- Parasitology Department, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, P.O. Box 30, Giza, 12411, Egypt
| | - Abdel-Nasser A Sabra
- Pharmacology Department, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, P.O. Box 30, Giza, 12411, Egypt
| | - Naglaa M El-Lakkany
- Pharmacology Department, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, P.O. Box 30, Giza, 12411, Egypt
| | - Sayed H Seif El-Din
- Pharmacology Department, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, P.O. Box 30, Giza, 12411, Egypt
| | | | | | - Antoni R Blaazer
- Medicinal Chemistry Vrije Universiteit Amsterdam (VUA), the Netherlands
| | - Erik de Heuvel
- Medicinal Chemistry Vrije Universiteit Amsterdam (VUA), the Netherlands
| | - Maarten Sijm
- Medicinal Chemistry Vrije Universiteit Amsterdam (VUA), the Netherlands
| | - Yang Zheng
- Medicinal Chemistry Vrije Universiteit Amsterdam (VUA), the Netherlands
| | | | - Jane C Munday
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, G12 8TA, UK
| | | | - Iwan J P de Esch
- Medicinal Chemistry Vrije Universiteit Amsterdam (VUA), the Netherlands
| | - Geert J Sterk
- Medicinal Chemistry Vrije Universiteit Amsterdam (VUA), the Netherlands
| | | | - Rob Leurs
- Medicinal Chemistry Vrije Universiteit Amsterdam (VUA), the Netherlands
| | - Carmen Gil
- Centro de Investigaciones Biológicas (CIB-CSIC), Madrid, Spain
| | - Harry P De Koning
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, G12 8TA, UK.
| |
Collapse
|
7
|
Sebastián-Pérez V, Hendrickx S, Munday JC, Kalejaiye T, Martínez A, Campillo NE, de Koning H, Caljon G, Maes L, Gil C. Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. Antimicrob Agents Chemother 2018; 62:e00603-18. [PMID: 30104270 PMCID: PMC6153811 DOI: 10.1128/aac.00603-18] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Accepted: 08/05/2018] [Indexed: 01/22/2023] Open
Abstract
The available treatments for leishmaniasis are less than optimal due to inadequate efficacy, toxic side effects, and the emergence of resistant strains, clearly endorsing the urgent need for discovery and development of novel drug candidates. Ideally, these should act via an alternative mechanism of action to avoid cross-resistance with the current drugs. As cyclic nucleotide-specific phosphodiesterases (PDEs) of Leishmania major have been postulated as putative drug targets, a series of potential inhibitors of Leishmania PDEs were explored. Several displayed potent and selective in vitro activity against L. infantum intracellular amastigotes. One imidazole derivative, compound 35, was shown to reduce the parasite loads in vivo and to increase the cellular cyclic AMP (cAMP) level at in a dose-dependent manner at just 2× and 5× the 50% inhibitory concentration (IC50), indicating a correlation between antileishmanial activity and increased cellular cAMP levels. Docking studies and molecular dynamics simulations pointed to imidazole 35 exerting its activity through PDE inhibition. This study establishes for the first time that inhibition of cAMP PDEs can potentially be exploited for new antileishmanial chemotherapy.
Collapse
Affiliation(s)
| | - Sarah Hendrickx
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, Belgium
| | - Jane C Munday
- Institute of Infection, Inflammation and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Titilola Kalejaiye
- Institute of Infection, Inflammation and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Ana Martínez
- Centro de Investigaciones Biológicas (CIB, CSIC), Madrid, Spain
| | | | - Harry de Koning
- Institute of Infection, Inflammation and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Guy Caljon
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, Belgium
| | - Louis Maes
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, Belgium
| | - Carmen Gil
- Centro de Investigaciones Biológicas (CIB, CSIC), Madrid, Spain
| |
Collapse
|
8
|
García AM, Brea J, González-García A, Pérez C, Cadavid MI, Loza MI, Martinez A, Gil C. Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. Molecules 2017; 22:molecules22091472. [PMID: 28869560 PMCID: PMC6151459 DOI: 10.3390/molecules22091472] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Revised: 09/01/2017] [Accepted: 09/01/2017] [Indexed: 11/16/2022] Open
Abstract
Phosphodiesterase (PDE) enzymes regulate the levels of cyclic nucleotides, cAMP, and/or cGMP, being attractive therapeutic targets. In order to modulate PDE activity in a selective way, we focused our efforts on the search of allosteric modulators. Based on the crystal structure of the PDE10A GAF-B domain, a virtual screening study allowed the discovery of new hits that were also tested experimentally, showing inhibitory activities in the micromolar range. Moreover, these new PDE10A inhibitors were able to decrease the nitrite production in LPS-stimulated cells, thus demonstrating their potential as anti-inflammatory agents.
Collapse
Affiliation(s)
- Ana M García
- Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain.
| | - José Brea
- Instituto de Farmacia Industrial, Facultad de Farmacia, Universidad de Santiago de Compostela, Campus Universitario Sur s/n, 15782 Santiago de Compostela, Spain.
| | - Alejandro González-García
- Instituto de Farmacia Industrial, Facultad de Farmacia, Universidad de Santiago de Compostela, Campus Universitario Sur s/n, 15782 Santiago de Compostela, Spain.
| | - Concepción Pérez
- Instituto de Química Médica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.
| | - María Isabel Cadavid
- Instituto de Farmacia Industrial, Facultad de Farmacia, Universidad de Santiago de Compostela, Campus Universitario Sur s/n, 15782 Santiago de Compostela, Spain.
| | - María Isabel Loza
- Instituto de Farmacia Industrial, Facultad de Farmacia, Universidad de Santiago de Compostela, Campus Universitario Sur s/n, 15782 Santiago de Compostela, Spain.
| | - Ana Martinez
- Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain.
| | - Carmen Gil
- Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain.
| |
Collapse
|
9
|
Neurodegenerative drug discovery: building on the past, looking to the future. Future Med Chem 2017; 9:707-709. [DOI: 10.4155/fmc-2017-0087] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|